Panitumumab, an anti-EGFR monoclonal antibody, demonstrated anti-tumor activity and tolerable safety profile in combination with gemcitabine and irinotecan in a phase II trial of patients with unresectable cholangiocarcinoma [16]. The gene discussed is EGFR; the disease is cholangiocarcinoma.